Predicted to have SH2 domain binding activity. Predicted to be involved in B cell activation; B cell receptor signaling pathway; and calcium-mediated signaling. Predicted to localize to membrane raft and plasma membrane. Human ortholog(s) of this gene implicated in Williams-Beuren syndrome. Orthologous to human LAT2 (linker for activation of T cells family member 2); INTERACTS WITH acetamide; ammonium chloride; bisphenol A.
LAT-2 like; linker for activation of B-cells; linker for activation of T-cells family member 2; non-T cell activation linker; non-T-cell activation linker; Ntal; Wbscr5; Williams-Beuren syndrome chromosome region 5 homolog; Williams-Beuren syndrome chromosome region 5 homolog (human); Williams-Beuren syndrome chromosome region 5-like protein
ixazomib inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein], ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]
methyl-beta-cyclodextrin promotes the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein]
wortmannin inhibits the reaction [[IL3 protein co-treated with CSF2 protein co-treated with FLT3LG protein co-treated with KITLG protein] results in increased expression of LAT2 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
